M

    Mereo BioPharma Group PLC ADR (MREO)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $0.27
    +0.01 (+5.66%)

    Market Cap: $40.32M

    Last updated: Sep 01, 2026 at 10:00 AM ET

    Earnings

    Performance (10Y)

    Beat Rate
    65%(13/20)
    Avg Surprise
    -93.61%
    Streak
    3 Q

    Upcoming Estimates

    Sep 30, 2026
    EPS Consensus$-0.01
    Range$-0.01 - $-0.01
    5 analysts
    EPS RevisionsNo revisions (7d)No revisions (30d)
    EPS Estimate Drift
    90d ago$0.00+100.0%
    60d ago$-0.01+0.0%
    30d ago$-0.01+0.0%
    7d ago$-0.01+0.0%
    Current$-0.01
    Revenue Consensus
    $0
    Range$0 - $0
    6 analysts
    Dec 31, 2026
    EPS Consensus$-0.03
    Range$-0.11 - $-0.01
    6 analysts
    Revenue Consensus
    $-5226330
    Range$-5226330 - $-5226330
    5 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$-0.03---
    Sep 26EST
    		-$-0.01---
    Jun 26
    		$-0.01$-0.01+0.00%Beat+0.0%
    Mar 26
    		$-0.01$-0.01+43.41%Beat+63.5%
    Dec 25
    		$-0.01$-0.01+0.00%Beat+0.0%
    Sep 25
    		$-0.01$0.01-175.19%Miss+50.0%
    Jun 25
    		$-0.01$-0.01+0.00%Beat+50.0%
    Mar 25
    		$-0.02$-0.01-100.00%Miss+68.7%
    Dec 24
    		$-0.01$-0.01+0.00%Beat+33.3%
    Sep 24
    		$-0.02$-0.01-100.00%Miss-
    Jun 24
    		$-0.02$-0.01-100.00%Miss+0.0%
    Mar 24
    		$-0.06$-0.01-539.00%Miss-
    Dec 23
    		$-0.01$-0.02+25.00%Beat+25.0%
    Sep 23
    		$0.00$0.00N/ABeat-100.0%
    Jun 23
    		$-0.02$-0.02+0.00%Beat+61.2%
    Mar 23
    		$0.00$0.00N/ABeat-100.0%
    Dec 22
    		$-0.02$-0.02+0.00%Beat+88.2%
    Sep 22
    		$0.06$-0.02+400.00%Beat+5900.0%
    Jun 22
    		$-0.05N/AN/ABeat-
    Mar 22
    		$0.00N/A+100.04%Beat+101.4%
    Dec 21
    		$-0.17$-0.03-466.67%Miss-301.9%
    Sep 21
    		$0.00N/A+100.04%Beat+100.4%
    Jun 21
    		$0.00N/A+100.00%Beat+100.0%
    Mar 21
    		$-0.14$-0.14+0.50%Beat+95.7%
    Dec 20
    		$0.08$0.00N/ABeat+102.6%
    Sep 20
    		$-0.24$0.00N/AMiss+59.3%
    Jun 20
    		$-0.23$0.00N/AMiss+58.7%
    Mar 20
    		$-3.28$-0.26-1160.38%Miss-369.1%
    Dec 19
    		$-3.29$0.00N/AMiss-359.0%
    Sep 19
    		$-0.59$0.00N/AMiss+12.5%
    Jun 19
    		$-0.54$0.00N/AMiss+20.5%
    Mar 19
    		$-0.70$0.00N/AMiss+11.8%
    Dec 18
    		$-0.72$0.00N/AMiss+14.9%
    Sep 18
    		$-0.67$0.00N/AMiss+12.4%
    Jun 18
    		$-0.69$0.00N/AMiss+9.8%
    Mar 18
    		$-0.79$0.00N/AMiss+28.1%
    Dec 17
    		$-0.84$0.00N/AMiss+20.6%
    Sep 17
    		$-0.77$0.00N/AMiss-17.6%
    Jun 17
    		$-0.76$0.00N/AMiss-
    Mar 17
    		$-1.10$0.00N/AMiss-
    Dec 16
    		$-1.06$0.00N/AMiss-
    Sep 16
    		$-0.65$0.00N/AMiss-

    Key Metrics

    Valuation
    P/E Ratio-7.15EV/EBITDA-1.21x
    Price/FCFN/AFCF YieldN/A
    Profitability
    Profit Margin0.00%Operating Margin0.00%
    ROE-67.80%ROIC-137.93%
    Financial Health
    Debt/Equity0.04xInterest Coverage-438.73x
    Current Ratio5.88xQuick Ratio5.88x
    Trading Statistics
    Beta0.30Avg Volume9.24M
    52-Week High$2.3752-Week Low$0.20

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$0.28
    SMA 20$0.29
    SMA 50$0.31
    SMA 200$0.60
    EMA 10$0.28
    EMA 20$0.29
    EMA 50$0.30
    EMA 200$0.65

    MACD

    Line: -0.01Signal: -0.01Hist: -0.00

    ADX

    ADX: 13.4+DI: 19.1-DI: 21.2

    Aroon & PSAR

    Aroon Up44.0
    Aroon Down96.0
    PSAR$0.33

    Bollinger Bands

    Upper Band$0.33
    Lower Band$0.26
    %B Position2559%(Upper)
    Band Width0.13

    RSI (14-Day)

    Neutral
    39.7

    Momentum Oscillators

    Stoch %K8.9
    Stoch %D8.8
    Williams %R-80.0
    ROC (10d)-13.3%
    Momentum-0.04
    CCI (20d)-133.4
    MFI (14d)22.2

    Volatility Measures

    ATR (14d)$0.02(9.2%)
    StdDev (20d)0.02
    Hist Vol74.2%(High)

    Volume Flow

    VWAP$0.27
    OBV17.5M
    AD Line146.6M
    CMF (20d)-0.492

    Volume Metrics

    Avg Vol (20d)9.7M
    Vol Ratio0.1x(Low)
    VWMA (20d)$0.30

    Pivot Points

    R3$0.29
    R2$0.28
    R1$0.27
    Pivot Point$0.26
    S1$0.25
    S2$0.24
    S3$0.22

    Advanced Oscillators

    TSI-14.81
    Ultimate Osc32.4
    KST-78.96

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total RevenueN/A$0$0$0$500,000$0$1.06M$0$0$0$1.00M$533,429
    Cost of RevenueN/A$304,488$591,144$1,000$132,000$271,036$271,459$284,892$257,288$274,842$-273,000$172,897
    Gross ProfitN/A$-304,488$-591,144$-1,000$368,000$-271,036$-271,459$-284,892$-257,288$-274,842$1.27M$360,532
    Operating Expenses$7.03M$8.45M$7.79M$10.01M$10.87M$11.20M$14.86M$9.37M$12.81M$9.90M$8.40M$7.03M
    R&D$1.81M$4.74M$4.19M$3.82M$5.37M$3.93M$8.74M$3.17M$4.95M$3.99M$4.80M$3.19M
    SG&A$5.22M$4.02M$4.20M$6.04M$5.49M$7.27M$6.45M$6.20M$7.87M$5.91M$3.60M$2.78M
    Operating Income$-7,030,000$-8,751,307$-8,377,878$-10,015,000$-10,499,000$-11,202,000$-15,133,368$-9,373,000$-12,814,000$-9,900,000$-7,128,000$-6,165,437
    Interest Income$0$327,000$421,000$504,000$589,000$659,000$881,000$983,000$559,000$617,000$763,000$689,000
    Interest Expense$16,000$20,000$22,966$27,831$24,000$180,000$375,000$353,000$331,000$310,000$353,000$700,000
    Income Before Tax$-7,005,000$-6,802,579$-7,812,696$-7,024,000$-14,616,000$-12,887,000$-7,551,327$-15,001,000$-12,255,000$-8,951,000$-9,641,000$-6,324,123
    Income Tax Expense$0$-94,840$-472,316$0$0$0$-570,659$-15,001,000$-369,413$-476,727$-532,000$235,580
    Net Income$-7,005,000$-6,707,738$-7,340,379$-7,024,000$-14,616,000$-12,887,000$-6,980,668$-15,001,000$-12,255,000$-8,951,000$-9,109,000$-6,559,704
    EBITDA$-6,989,000$-8,446,819$-7,786,734$-9,815,000$-14,294,000$-12,437,000$-6,908,343$-14,366,000$-11,667,000$-8,641,000$-9,007,000$-7,279,826
    EBITN/A$-8,751,307$-8,377,878$-9,869,000$-14,592,000$-12,707,000$-7,179,802$-14,648,000$-11,924,000$-8,641,000$-9,288,000$-7,521,945
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about MREO

    News

    Mereo BioPharma Group plc - American Depositary Shares (NQ: MREO)

    This article provides recent news headlines and stock information for Mereo BioPharma Group plc (MREO). It highlights press releases from Rubric Capital Management regarding their proposed director nominees and an open letter to shareholders in late 2022. The stock quote shows MREO trading at 0.2866, down 1.17%.

    The Chronicle-Journal•8/22/26•
    Neutral

    Form 8K MEREO BIOPHARMA GROUP PLC For: 19 August By Investing.com

    This article reports on the filing of a Form 8K by Mereo BioPharma Group PLC for August 19th. The content primarily consists of market data, news links, and navigation typical of a financial news portal, with the main subject being the Form 8K filing.

    Investing.com Canada•8/19/26•
    Neutral

    Mereo BioPharma gets Nasdaq extension to regain $1 minimum bid compliance

    Mereo BioPharma has received an extension from Nasdaq until February 16, 2027, to meet the $1 minimum bid-price requirement for its ADSs. To comply, the closing bid price must remain at $1 or more for at least ten consecutive business days. Failure to meet this deadline could result in a delisting notice, though the current notices do not immediately affect its Nasdaq Capital Market listing.

    Bitget•8/19/26•
    Neutral

    Mereo BioPharma Group's (MREO) "Underweight" Rating Reiterated at JPMorgan Chase & Co.

    JPMorgan Chase & Co. has reiterated its "underweight" rating for Mereo BioPharma Group (MREO), despite "buy" ratings from other firms like Needham and BTIG. The stock holds an overall "Hold" rating from analysts with an average price target of $3.25. Mereo BioPharma Group reported quarterly earnings of -$0.01 per share, meeting analyst estimates, and institutional investors own 62.83% of the company's stock.

    MarketBeat•8/19/26•
    Somewhat-Bearish

    Mereo BioPharma (NASDAQ: MREO) given 2027 Nasdaq deadline

    Mereo BioPharma Group plc (MREO) has received a second notice from Nasdaq regarding its failure to meet the minimum $1.00 bid price requirement. The company has been granted an additional 180-day compliance period, until February 16, 2027, to regain compliance by achieving a closing bid price of at least $1.00 for 10 consecutive business days. Failure to meet this requirement could lead to delisting, though Mereo would have the option to appeal.

    Stock Titan•8/19/26•
    Somewhat-Bearish

    Frequently Asked Questions About MREO

    Does MREO pay dividends?
    Mereo BioPharma Group PLC ADR (MREO) does not currently pay a regular dividend.
    What is MREO's market cap?
    Mereo BioPharma Group PLC ADR (MREO) has a market capitalization of $40.32M with a current stock price of $0.27.

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In